Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27771994 | 0.85 | APOBEC3G (0.31) | — | |
| SCHEMBL31167597 | 0.84 | MEP1A (0.31) | GPR84MEP1AMEP1B | |
| SCHEMBL31719921 | 0.80 | PDCD1 (0.33) | — | |
| SCHEMBL698604 | 0.80 | CES2 (0.41) | GPR84CES2CES1RIPK1 | |
| SCHEMBL29780412 | 0.80 | CES2 (0.41) | GPR84CES2CES1RIPK1 | |
| SCHEMBL31615014 | 0.77 | DRD4 (0.33) | — | |
| SCHEMBL17295763 | 0.77 | MEP1B (0.35) | MEP1AMEP1B | |
| SCHEMBL21857947 | 0.77 | — | — | |
| SCHEMBL3310848 | 0.76 | CES2 (0.38) | GPR84CES2CES1RIPK1 | |
| SCHEMBL20607946 | 0.76 | CES2 (0.33) | GPR84CES2CES1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118556063-A | Heterocyclic compound, pharmaceutical composition and application thereof | 上海湃隆生物科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023138583-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2021254417-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-12-23 | — | — | WO | disclosed |
| WO-2021254416-A1 | INDANONE COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-2892893-B2 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| EP-2892893-B2 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| EP-2892893-B1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2892893-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| US-20050256177-A1 | Phenyl derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | CYP2B6, HAVCR2, CYP2D6 | GPR84 1007/4885CES2 1990/4885CES1 260/4885 |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | CYP2B6, HAVCR2, CYP2D6 | GPR84 1007/4885CES2 1990/4885CES1 260/4885 |
| US-20050256177-A1 | Phenyl derivatives for the treatment of abnormal cell growth | CCND3, CDC25C, CCNA1 | GPR84 4028/4885CES2 1621/4885CES1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.